PRME Prime Medicine, Inc.
$4.35▲ +20.50%
Healthcare
Other
Pre-market
$4.27▼ -1.79%
Oct 28, 5:45 AM ET
Volume 8.81M
Avg Volume (10D) 4.58M
Key Metrics & Fundamentals
Market Cap
$788.99M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.67 - 5.11
% vs 50 MA
26.90%
% vs 200 MA
24.97%
RSI-14
63.7
MACD Histogram
+0.0500
Beta (1Y vs SPY)
2.33
Free Cash Flow
-$41.09M
Gross Rev
$1.15M
Gross Profit
$1.15M
EBITDA
-$41.50M
COGS
–
Operating Exp
$44.44M
Operating Income
-$43.29M
EBIT
-$43.29M
Pretax Income
-$42.11M
Net Income
-$42.11M
EPS (Diluted)
-0.24
Price & Volume History
Loading chart…
Recent News
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Zacks · Oct 12, 2026 11:24 AM ET
Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment
MT Newswires · Oct 5, 2026 9:14 AM ET
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
GlobeNewswire · Oct 5, 2026 8:00 AM ET
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Barchart · Sep 29, 2026 9:00 AM ET
Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says
MT Newswires · Sep 25, 2026 1:12 PM ET
Prime Medicine stock surges on FDA IND clearance
Investing.com · Sep 24, 2026 4:47 PM ET
Prime Medicine Says US FDA Clears PM647 IND for Alpha-1 Antitrypsin Deficiency; Shares Rise After Hours
MT Newswires · Sep 24, 2026 4:32 PM ET
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
GlobeNewswire · Sep 24, 2026 4:01 PM ET
Anthropic AI Discovery Gene-Editing Stocks Falling
GuruFocus.com · Sep 24, 2026 8:46 AM ET
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
Stocktwits · Sep 23, 2026 5:49 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See PRME's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.